By exploring these molecular and genetic pathways, we aimed to provide insights into the therapeutic potential of targeting FOXP3 in combination with chemotherapeutic agents to overcome resistance in ovarian cancer cells. This evidence concerns the gene FOXP3 and ovarian carcinoma.